Lloyd Price
- Dec 7, 2023

Corporate Venture Capital's growing role and importance in HealthTech

Exec Summary:

Corporate venture capital (CVC) plays an increasingly significant role in the healthtech industry, providing funding, expertise, and strategic partnerships to innovative startups. As healthcare giants and technology companies recognize the transformative potential of healthtech, they are actively investing in these ventures, shaping the future of healthcare delivery and innovation.

Motivations for Corporate Venture Capital in Healthtech

Several factors drive the growing involvement of CVC in the healthtech sector:

Strategic Innovation: Healthtech startups offer a fertile ground for healthcare companies to explore new technologies, business models, and solutions to unmet medical needs. CVC investments provide access to cutting-edge innovations and potential future partners.
Market Expansion: CVC can help healthcare companies expand into new markets and patient segments. By investing in healthtech startups, they can gain access to new technologies, expertise, and customer bases.
Competitive Landscape: In an increasingly competitive healthcare landscape, CVC investments allow companies to stay ahead of the curve and maintain a leading position in the market.
Financial Returns: CVC investments in healthtech startups can generate attractive financial returns, as the healthtech sector holds immense growth potential.

Benefits of Corporate Venture Capital for Healthtech Startups

Healthtech startups can reap numerous benefits from partnering with CVC firms, including:

Funding: CVC investments provide crucial funding to support the development and growth of healthtech startups.
Strategic Expertise: CVC firms offer valuable expertise in healthcare, business development, and regulatory matters, guiding startups through complex challenges.
Market Access: CVC firms can connect startups with their extensive networks of healthcare providers, payers, and partners, facilitating market access and partnerships.
Validation and Credibility: CVC investments provide validation and credibility to healthtech startups, enhancing their reputation and attracting further investment.

Examples of Corporate Venture Capital in Healthtech

Numerous notable examples highlight the active involvement of CVC in the healthtech sector:

Johnson & Johnson Innovation: Through its CVC arm, Johnson & Johnson has invested in over 200 healthtech startups, focusing on areas such as digital health, medical devices, and biotechnology.
Google Ventures: Google Ventures has invested in several promising healthtech startups, including Verily Life Sciences, 23andMe, and Flatiron Health, demonstrating its commitment to healthcare innovation.
GE Ventures: GE Ventures has a strong track record of investing in healthtech startups, including Castlight Health, Evidation Health, and Pear Therapeutics, focusing on areas such as data analytics, precision medicine, and digital therapeutics.
Merck Ventures: Merck Ventures has invested in a range of healthtech startups, including Clue, GlycoMimetics, and AbCellera, demonstrating its interest in areas such as women's health, oncology, and immunotherapy.
Samsung Ventures: Samsung Ventures has invested in several healthtech startups, including Lyra Health, Pear Therapeutics, and 2Morrow, focusing on areas such as mental health, digital therapeutics, and personalized medicine.

These examples illustrate the diverse range of CVC investments in healthtech, encompassing a wide spectrum of technologies and therapeutic areas.

Future of Corporate Venture Capital in Healthtech

CVC is expected to continue playing a prominent role in the healthtech industry, driven by the increasing importance of innovation and the growing potential of healthtech to transform healthcare delivery.

CVC firms will continue to seek out promising startups, providing them with the funding, expertise, and strategic partnerships needed to succeed.

As the healthtech sector matures, CVC investments are likely to focus on areas such as artificial intelligence, machine learning, data analytics, and personalised medicine, shaping the future of healthcare.

Corporate Development for Healthcare Technology companies in EMEA

Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital

HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk

HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb

HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

Corporate Venture Capital well-suited to investing in HealthTech companies

Corporate venture capital (CVC) has been playing an increasingly important role in the HealthTech industry in recent years. This is due to a number of factors, including:

The growing maturity of the HealthTech market: The HealthTech industry has become increasingly attractive to investors, as the market has matured and demonstrated strong growth potential. This has made CVCs more interested in investing in HealthTech companies, as they believe that these companies have a higher likelihood of success.
The need for corporate innovation: Many large companies are looking to HealthTech for new sources of innovation. CVCs can help these companies to identify and invest in promising HealthTech startups, which can then provide their parent companies with access to new technologies and markets.
The need for faster innovation cycles: The speed of innovation in the HealthTech industry is accelerating, and CVCs can help companies to move more quickly from idea to market. This is because CVCs have access to a network of experts and resources that can help companies to overcome the challenges of developing and commercializing new technologies.

As a result of these factors, CVC funding for HealthTech companies has been growing rapidly in recent years. According to PitchBook, CVC investment in HealthTech reached $7.7 billion in 2020, up from $2.7 billion in 2015.

There are a number of reasons why CVCs are particularly well-suited to investing in HealthTech companies. CVCs have a number of advantages over traditional venture capitalists, including:

Deep industry knowledge: CVCs are often affiliated with large companies that have deep experience in the healthcare industry. This gives them a better understanding of the needs and challenges of healthcare providers and patients.
Access to markets and distribution channels: CVCs have access to the markets and distribution channels of their parent companies. This can help HealthTech startups to get their products into the hands of patients more quickly and easily.
Mentorship and support: CVCs can provide HealthTech startups with mentorship and support from experienced executives and industry experts. This can help companies to overcome challenges and grow their businesses more effectively.

As a result of these advantages, CVCs are playing an increasingly important role in the development of new HealthTech solutions. They are helping to bring innovative technologies to market that are improving the lives of patients and making healthcare more affordable and accessible.

Corporate Venture Capital success in HealthTech

Corporate venture capital (CVC) has played a significant role in the growth and success of many HealthTech companies. CVCs bring a unique set of advantages to the table, including deep industry knowledge, access to markets and distribution channels, and mentorship and support from experienced executives and industry experts.

These advantages have helped CVC-backed HealthTech startups to achieve significant success, as evidenced by numerous notable exits and acquisitions.

Examples of CVC success in HealthTech:

Denali Therapeutics: Founded in 2014, Denali Therapeutics is a clinical-stage biotechnology company developing novel therapies for neurodegenerative diseases. The company has raised over $1.3 billion in funding, including investments from CVCs such as Johnson & Johnson Innovation (JJI) and Amgen Ventures. In 2022, Denali Therapeutics partnered with Pfizer to develop a potential treatment for Alzheimer's disease.
Omada Health: Founded in 2012, Omada Health is a digital health company that provides personalized weight management programs for adults. The company has raised over $400 million in funding, including investments from CVCs such as McKesson Ventures and Kaiser Permanente Ventures. In 2021, Omada Health was acquired by UnitedHealth Group for $5 billion.
Oscar Health: Founded in 2012, Oscar Health is an online health insurance marketplace that provides personalized coverage and support to its members. The company has raised over $4 billion in funding, including investments from CVCs such as Google Ventures and General Atlantic. In 2022, Oscar Health went public on the Nasdaq stock exchange.
Grail: Founded in 2015, Grail is a biotechnology company developing a non-invasive blood test for early-stage cancer detection. The company has raised over $2.5 billion in funding, including investments from CVCs such as Johnson & Johnson Innovation and Illumina Ventures. In 2022, Grail was acquired by Illumina for $8 billion.

These are just a few examples of the many CVC-backed HealthTech companies that have achieved significant success. CVCs continue to play a vital role in driving innovation and improving patient care in the HealthTech industry.

Factors contributing to CVC success in HealthTech:

Deep industry knowledge: CVCs are often affiliated with large companies that have deep experience in the healthcare industry. This gives them a better understanding of the needs and challenges of healthcare providers and patients.
Access to markets and distribution channels: CVCs have access to the markets and distribution channels of their parent companies. This can help HealthTech startups to get their products into the hands of patients more quickly and easily.
Mentorship and support: CVCs can provide HealthTech startups with mentorship and support from experienced executives and industry experts. This can help companies to overcome challenges and grow their businesses more effectively.
Long-term investment horizon: CVCs are often willing to invest in HealthTech companies with longer-term timelines for success. This is because they are aligned with the long-term growth strategies of their parent companies.

Future of Corporate Venture Capital in HealthTech

The future of corporate venture capital (CVC) in HealthTech is bright. CVCs are well-positioned to continue playing a significant role in driving innovation and improving patient care in the HealthTech industry. Here are some of the key trends that are shaping the future of CVC in HealthTech:

Increased focus on early-stage investments: CVCs are increasingly investing in early-stage HealthTech companies, as they believe that these companies have the most potential for disruption and growth. This is a departure from the traditional CVC model, which has been more focused on later-stage investments.
Greater collaboration with traditional venture capitalists (VCs): CVCs are increasingly collaborating with traditional VCs to invest in HealthTech companies. This is a strategic move, as it allows CVCs to tap into the expertise and network of VCs while still maintaining control over their investments.
Emphasis on value creation: CVCs are placing a greater emphasis on value creation, as they are under increasing pressure to demonstrate the return on their investments. This means that CVCs are focusing on investments that have the potential to generate significant revenue for their parent companies.
Investment in digital health and artificial intelligence (AI): CVCs are showing a strong interest in investing in digital health and AI startups. These technologies have the potential to revolutionize the healthcare industry, and CVCs are well-positioned to identify and invest in promising companies in these areas.

Overall, the future of CVC in HealthTech is promising. CVCs have a unique set of advantages that make them well-suited to investing in HealthTech companies. As the industry continues to grow and evolve, CVCs are likely to play an even more important role in driving innovation and improving patient care.

Here are some specific areas where CVCs are likely to focus in the future of HealthTech:

Preventive care and chronic disease management: CVCs are interested in investing in companies that are developing innovative solutions for preventing and managing chronic diseases, such as diabetes, heart disease, and cancer.
Personalized medicine: CVCs are interested in investing in companies that are developing personalized medicine solutions, such as gene therapy and precision medicine.
Mental health and behavioral health: CVCs are interested in investing in companies that are developing innovative solutions for mental health and behavioral health disorders.
AI and machine learning (ML) in healthcare: CVCs are interested in investing in companies that are using AI and ML to improve healthcare delivery, such as clinical decision support systems and predictive analytics.

As these areas continue to develop, CVCs are likely to play a key role in driving innovation and improving patient care. They have the resources, expertise, and network to identify and invest in promising companies that are developing the next generation of HealthTech solutions.